Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

Biotechnology • Healthcare • Iselin, NJ, United States • OTLK (NCM)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

609 619 3990 111 S. Wood Avenue, Iselin, NJ 08830, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again (NASDAQ:OTLK) - Seeking Alpha
Seeking Alpha • Dec 29
Outlook Therapeutics Announces New Employment Inducement Grants - Sahm
Sahm • Dec 28
Biotech offers stock options to lure two new hires at $2.01 a share - Stock Titan
Stock Titan • Dec 26
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics - Ophthalmology Times
Ophthalmology Times • Nov 13
Outlook Therapeutics Grants Stock Options to New Employees as Part of Inducement Package - Quiver Quantitative
Quiver Quantitative • Dec 26

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Outlook Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Outlook Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Outlook Therapeutics, Inc. have?
Outlook Therapeutics, Inc. has approximately 17 employees.
What industry is Outlook Therapeutics, Inc. in?
Outlook Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Outlook Therapeutics, Inc. a publicly traded company?
Yes, Outlook Therapeutics, Inc. is publicly traded under the ticker symbol OTLK on the NCM. The company has a market capitalization of approximately $0.12 billion.
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc. is headquartered in Iselin, NJ, United States at 111 S. Wood Avenue, Iselin, NJ 08830, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.